Overcoming data-driven challenges to minimize toxicity in gene therapy development
04 May 2026
Gene Therapy Development
- Does the physical titer or genome titer correlate with (or match) the functional titer?
- How is rAAV genome integrity characterized, specifically with respect to partial versus full-length genomes?
- What residual plasmid impurities or reverse packaging species are present, and how do they impact drug potency?
- How are host genomic DNA impurities detected and characterized?
